Solvay
2019 Annual Integrated Report

Accounting policy

IFRS 15 establishes a five-step model to account for revenue arising from contracts with customers:

  • identify the contract;
  • identify the performance obligations;
  • determine the transaction price;
  • allocate the transaction price to the performance obligations in the contract; and
  • recognize revenue when or as the Group satisfies a performance obligation.

Under IFRS 15, revenue is recognized at an amount that reflects the consideration to which the Group expects to be entitled in exchange for transferring goods or services to a customer.

Sale of goods: Contracts can be short term (including based only on a purchase order) or long term, some have minimum off-take requirements. As the Group is in the business of selling chemicals, contracts with customers generally concern the sale of goods. As a result, revenue recognition generally occurs at a point in time when control of the chemicals is transferred to the customer, generally on delivery of the goods.

Distinct elements: a good or service that is promised to a customer is distinct if both of the following criteria are met: (a) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e. the good or service is capable of being distinct); and (b) the Group’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e. the promise to transfer the good or service is distinct within the context of the contract).

The revenue of the Group consists mainly of sales of chemicals, which qualify as separate performance obligations. Value-added services – mainly customer assistance services – corresponding to Solvay’s know-how are rendered predominantly over the period that the corresponding goods are sold to the customer.

Variable consideration: some contracts with customers provide trade discounts or volume rebates. Trade discounts and volume rebates give rise to variable consideration under IFRS 15, and are required to be estimated at contract inception and subsequently at each reporting date. IFRS 15 requires the estimated variable consideration to be constrained to prevent overstatement of revenue.

Moment of recognition of revenue: revenue is recognized when (or as) the Group satisfies a performance obligation by transferring a promised good or service (ie an asset) to a customer. An asset is transferred when (or as) the customer obtains control of that asset. Substantially all revenue stems from performance obligations satisfied at a point in time, i.e. the sale of goods. Revenue recognition for those takes into account the following:

  • the Group has a present right to payment for the asset;
  • the customer has legal title to the asset;
  • the Group has transferred physical possession of the asset;
  • the customer has the significant risks and rewards of ownership of the asset (in this respect, incoterms are considered); and
  • the customer has accepted the asset.

The Group sells its chemicals to its customers, (a) directly, (b) through distributors, and (c) with the assistance of agents. When the Group delivers a product to distributors for sale to end customers, the Group evaluates whether that distributor has obtained control of the product at that point in time. No revenue is recognized upon delivery of a product to a customer or distributor if the delivered product is held on consignment. Indicators of consignment inventory include:

  • the product is controlled by the Group until a specified event occurs, such as the sale of the product to a customer of the distributor or until a specified period expires;
  • the Group is able to require the return of the product or transfer the product to a third party (such as another distributor); and
  • the distributor does not have an unconditional obligation to pay for the product (although he might be required to pay a deposit).

Agents facilitate sales and do not purchase and resell the goods to the end customer.

Products sold to customers generally cannot be returned, other than for performance deficiencies. Customer acceptance clauses are in many cases a formality that would not affect the Group’s determination of when the customer has obtained control of the goods.

Revenue from services is recognized in the period those services have been rendered.

Warranties: warranties provide a customer with assurance that the related product will function as the parties intended because it complies with agreed-upon specifications. Substantially all warranties do not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications, and are hence accounted for in accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets.

An Operating Segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, whose operating results are regularly reviewed by the entity’s chief operating decision maker and for which discrete financial information is available. The Solvay Group’s chief operating decision maker is the Chief Executive Officer.

General

Solvay is organized into four Operating Segments:

  • Advanced Materials offers high-performance materials for multiple applications primarily in the automotive, aerospace, electronics, and health markets. It particularly provides sustainable mobility solutions, reducing weight and improving CO2 and energy efficiency.
  • Advanced Formulations primarily serves the consumer goods, agro and food, as well as energy markets. It offers customized specialty formulations that impact surface chemistry and alter liquid behavior, to optimize efficiency and yield, while minimizing the environmental impact.
  • Performance Chemicals operates in mature and resilient markets and has leading positions in chemical intermediates. Success is based on economies of scale and state-of-the-art production technology. It mainly serves the consumer goods and food markets.
  • Corporate & Business Services includes corporate and other business services, such as the Research & Innovation Center, and energy services.

We refer to the Business Review for more information on Operating Segments, GBUs figures, and new definition of Operating Segments (effective as from 2020).

External net sales by cluster

In € million

2019

2018

Advanced Materials

4,512

4,385

Specialty Polymers

1,927

2,009

Composite Materials

1,272

1,082

Silica

449

442

Special Chem

864

852

Advanced Formulations

2,846

3,057

Novecare

1,789

2,000

Technology Solutions

632

643

Aroma Performance

425

414

Performance Chemicals

2,879

2,808

Soda Ash & Derivatives

1,661

1,562

Peroxides

683

654

Coatis

455

509

Functional Polymers

80

82

Corporate & Business Services

6

7

CBS and NBD

6

7

Total

10,244

10,257

Sales by market

Sales by market are presented in the Business Review, see note B1.

Net sales by country and region

The sales disclosed below are allocated based on the customers’ location.

In € million

2019

%

2018

%

Belgium

138

1%

153

1%

Germany

711

7%

727

7%

Italy

438

4%

444

4%

France

397

4%

402

4%

Netherlands

99

1%

105

1%

United Kingdom

287

3%

279

3%

Spain

177

2%

191

2%

European Union – Other

519

5%

501

5%

European Union

2,765

27%

2,802

27%

Europe – Other

94

1%

103

1%

United States

2,896

28%

3,001

29%

Canada

165

2%

160

2%

North America

3,061

30%

3,161

31%

Brazil

693

7%

681

7%

Mexico

222

2%

193

2%

Latin America – Other

254

2%

234

2%

Latin America

1,169

11%

1,108

11%

Australia

100

1%

100

1%

China

962

9%

942

9%

Hong Kong

50

0%

77

1%

India

198

2%

191

2%

Indonesia

97

1%

105

1%

Japan

360

4%

357

3%

Russia

55

1%

62

1%

Saudi Arabia

122

1%

110

1%

South Korea

297

3%

279

3%

Thailand

188

2%

177

2%

Turkey

74

1%

73

1%

Other

650

6%

610

6%

Asia and rest of the world

3,153

31%

3,083

30%

Total

10,244

100%

10,257

100%

Information per segment

2019
In € million
Income statement items

Advanced Materials

Advanced Formulations

Performance Chemicals

Corpo­rate & Business Services

Group Total

(1)

Underlying EBITDA is a key performance indicator followed by management and includes other elements than those presented above (see Business Review section – Reconciliation of underlying with IFRS figures).

Net sales (including inter-segment sales)

4,513

2,849

2,905

6

10,273

Inter-segment sales

 

(3)

(26)

 

(30)

Net sales

4,512

2,846

2,879

6

10,244

Revenue from non-core activities

43

17

280

643

983

Gross margin

1,440

728

794

21

2,983

Depreciation and amortization

464

1,105

228

109

1,906

Earnings from associates and joint ventures

8

9

77

1

95

Underlying EBITDA(1)

1,143

490

852

(163)

2,322

EBIT

 

 

 

 

316

Net financial charges

 

 

 

 

(242)

Income taxes

 

 

 

 

(153)

Profit for the year from discontinued operations

 

 

 

 

236

Profit for the year

 

 

 

 

157

2019
In € million
Statement of financial position and other items

Advanced Materials

Advanced Formulations

Performance Chemicals

Corpo­rate & Business Services

Group Total

Capital expenditures (continuing operations)

375

155

177

119

826

Capital expenditures (discontinued operations)

 

 

141

 

141

Investments (continuing operations)

4

2

11

6

23

 

 

 

 

 

 

Working capital

 

 

 

 

 

Inventories

839

379

359

9

1,587

Trade receivables

555

349

452

58

1,414

Trade payables

397

288

363

229

1,277

Capital expenditures are related to property, plant and equipment, right-of-use assets, and intangible assets.

Investments include acquisitions of subsidiaries and other investments (joint operations, joint ventures and associates).

2018
In € million
Income statement items

Advanced Materials

Advanced Formulations

Performance Chemicals

Corpo­rate & Business Services

Group Total

(1)

Underlying EBITDA is a key performance indicator followed by management and includes other elements than those presented above (see Business Review section – Reconciliation of underlying with IFRS figures).

Net sales (including inter-segment sales)

4,386

3,060

2,831

7

10,283

Inter-segment sales

 

(3)

(23)

 

(26)

Net sales

4,385

3,057

2,808

7

10,257

Revenue from non-core activities

33

19

312

678

1,042

Gross margin

1,474

787

737

37

3,035

Depreciation and amortization

435

264

198

47

944

Earnings from associates and joint ventures

10

5

27

1

44

Underlying EBITDA(1)

1,197

521

729

(218)

2,230

EBIT

 

 

 

 

986

Net financial charges

 

 

 

 

(195)

Income taxes

 

 

 

 

(75)

Profit for the year from discontinued operations

 

 

 

 

201

Profit for the year

 

 

 

 

917

2018
In € million
Statement of financial position and other items

Advanced Materials

Advanced Formulations

Performance Chemicals

Corpo­rate & Business Services

Group Total

Capital expenditures (continuing operations)

355

148

149

58

711

Capital expenditures (discontinued operations)

 

 

122

 

122

Investments (continuing operations)

12

 

 

4

16

 

 

 

 

 

 

Working capital

 

 

 

 

 

Inventories

900

446

326

13

1,685

Trade receivables

535

396

482

21

1,434

Trade payables

437

345

381

275

1,439

Capital expenditures are related to property, plant and equipment and intangible assets.

Investments include acquisitions of subsidiaries and other investments (joint operations, joint ventures and associates).

Non-current assets, capital expenditures and investments by country and region (continuing operations)

 

Non-current assets

Capital expenditures and investments

In € million

2019

%

2018

%

2019

%

2018

%

Belgium

253

2%

304

2%

(96)

11%

(51)

7%

Germany

438

3%

402

3%

(45)

5%

(33)

5%

Italy

635

5%

581

4%

(85)

10%

(74)

10%

France

2,883

21%

2,906

21%

(116)

14%

(111)

15%

United Kingdom

221

2%

207

1%

(19)

2%

(28)

4%

Spain

144

1%

140

1%

(19)

2%

(15)

2%

European Union – Other

327

2%

304

2%

(25)

3%

(20)

3%

European Union

4,900

36%

4,844

35%

(405)

48%

(332)

46%

Europe – Other

 

0%

 

0%

(18)

2%

1

0%

United States

6,710

49%

7,239

52%

(290)

34%

(249)

34%

Canada

185

1%

176

1%

(11)

1%

(11)

2%

North America

6,896

50%

7,415

53%

(301)

35%

(261)

36%

Brazil

266

2%

256

2%

(26)

3%

(30)

4%

Latin America – Other

40

0%

36

0%

(3)

0%

(8)

1%

Latin America

306

2%

292

2%

(29)

3%

(38)

5%

Russia

245

2%

168

1%

 

0%

 

0%

Thailand

135

1%

123

1%

(5)

1%

(6)

1%

China

563

4%

579

4%

(47)

6%

(41)

6%

South Korea

123

1%

123

1%

(11)

1%

(8)

1%

India

264

2%

234

2%

(23)

3%

(35)

5%

Singapore

50

0%

42

0%

(3)

0%

(1)

0%

Japan

22

0%

18

0%

(3)

0%

(2)

0%

Other

175

1%

184

1%

(2)

0%

(3)

0%

Asia and rest of the world

1,576

12%

1,470

10%

(95)

11%

(96)

13%

Total

13,677

100%

14,022

100%

(848)

100%

(727)

100%

Non-current assets are those other than deferred tax assets, loans and other assets. Capital expenditures and investments include acquisitions of property, plant and equipment, right-of-use assets (2019 only), intangible assets and investments in subsidiaries and other investments (joint operations, joint ventures and associates). Both exclude discontinued operations.